H.C. Wainwright lowered the firm’s price target on Santhera Pharmaceuticals to CHF 25 from CHF 30 and keeps a Buy rating on the shares. The company completed multiple transactions completed, providing an operational runway through to potential cash flow breakeven, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks